Safety of recombinant activated factor VII in randomized clinical trials [1]

New England Journal of Medicine

Volumn 364, Issue 6, 2011, Pages 574-576

  Patel, Amit ^a   Cooper, Nichola ^a   Laffan, Michael A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT;

ARTERY THROMBOSIS; BLEEDING; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; GROUPS BY AGE; HUMAN; LETTER; OFF LABEL DRUG USE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGED; CHEMICALLY INDUCED DISORDER; MORTALITY; NOTE; THROMBOEMBOLISM;

AGED; FACTOR VIIA; HEMORRHAGE; HEMOSTATICS; HUMANS; OFF-LABEL USE; THROMBOEMBOLISM;

EID: 79851500675     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1013591     Document Type: Letter

References (1)

1. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010;363:1791-800.